Literature DB >> 33478325

MiR-302b Suppresses Tumor Metastasis by Targeting Frizzled 6 in OSCC.

S Sun1, J Wang1, J Liu1,2, F Yin1, C Xin1, X Zeng1, J Li1, Q Chen1.   

Abstract

Oral squamous cell carcinoma (OSCC) accounts for approximately 90% of malignant epithelial tumors of the oral and maxillofacial region. OSCC has high rate of metastasis and poor prognosis. Tobacco and/or alcohol consumption and human papillomavirus infection are relatively exact susceptibility factors for OSCC, but the specific process of oral mucosal carcinogenesis and progression is very complicated. microRNA-302b (miR-302b) could regulate various characteristics of many tumor cells, such as proliferation and apoptosis, but its role and mechanism in OSCC have not been reported. This research aims to study the effect of miR-302b on the invasion and migration ability of OSCC and the mechanism by which it functions as well as to identify new prognostic indicators and therapeutic targets for OSCC patients. Functional studies showed that the miR-302b level was negatively correlated with the invasion and migration ability of OSCC. The studies also showed that the overexpression of miR-302b could attenuate the invasion and migration ability of OSCC cells and reduce lymphangiogenesis and the lung metastasis rate of OSCC cells in a mouse model. Mechanistic studies were performed by quantitative polymerase chain reactions, luciferase assays, and RNA pull-down experiments. The results verified that frizzled class receptor 6 (FZD6) is a target gene of miR-302b in OSCC that could promote cell invasion and migration. Clinical studies demonstrate that the protein expression level of FZD6 was higher in OSCC and metastatic lymph nodes than in normal oral mucosa epithelium. Taken together, these data showed that miR-302b could inhibit the invasion and migration ability of OSCC cells by targeting and downregulating FZD6, thereby inhibiting OSCC metastasis. As a new target gene of miR-302b, FZD6 has the potential to become a prognostic and therapeutic target for OSCC patients.

Entities:  

Keywords:  FZD6; invasion; microRNA-302b; migration; oral squamous cell carcinoma; prognosis

Mesh:

Substances:

Year:  2021        PMID: 33478325     DOI: 10.1177/0022034520986551

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  5 in total

1.  Circulating microRNAs Suggest Networks Associated with Biological Functions in Aggressive Refractory Type 2 Celiac Disease.

Authors:  Nicoletta Bianchi; Luisa Doneda; Luca Elli; Cristian Taccioli; Valentina Vaira; Alice Scricciolo; Vincenza Lombardo; Anna Terrazzan; Patrizia Colapietro; Leonardo Terranova; Carlo Bergamini; Maurizio Vecchi; Lucia Scaramella; Nicoletta Nandi; Leda Roncoroni
Journal:  Biomedicines       Date:  2022-06-14

2.  miR-34c-5p mediates the cellular malignant behaviors of oral squamous cell carcinoma through targeted binding of TRIM29.

Authors:  Yuchen Shen; Changsheng Sun; Bowen Zhao; Haobing Guo; Jianhao Li; Yanyun Xia; Miaomiao Liu; Songlin Piao; Wuliji Saiyin
Journal:  Ann Transl Med       Date:  2021-10

3.  Procyanidin B2 inhibits angiogenesis and cell growth in oral squamous cell carcinoma cells through the vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) pathway.

Authors:  Qiurong Sun; Taiyang Zhang; Qingchun Xiao; Bingxin Mei; Xingwang Zhang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

4.  The Prognostic Value of the Developmental Gene FZD6 in Young Saudi Breast Cancer Patients: A Biomarkers Discovery and Cancer Inducers OncoScreen Approach.

Authors:  Mourad Assidi; Abdelbaset Buhmeida; Maryam H Al-Zahrani; Jaudah Al-Maghrabi; Mahmood Rasool; Muhammad I Naseer; Heba Alkhatabi; Abdulmajeed F Alrefaei; Ali Zari; Razan Elkhatib; Adel Abuzenadah; Peter N Pushparaj; Muhammad Abu-Elmagd
Journal:  Front Mol Biosci       Date:  2022-02-14

5.  METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.

Authors:  Yilong Ai; Shiwei Liu; Hailing Luo; Siyuan Wu; Haigang Wei; Zhe Tang; Xia Li; Xiaozhi Lv; Chen Zou
Journal:  J Immunol Res       Date:  2021-08-23       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.